Abstract 2665: Reduction in Frequency of Left Ventricular Dysfunction in Patients with ST Elevation Myocardial Infarction Undergoing PCI Treated with Caldaret (MCC-135)
Primary coronary intervention (PCI) reduces myocardial damage in patients with ST elevation myocardial infarction (STEMI). However, cellular reperfusion injury associated with calcium overload may limit myocardial salvage. We previously showed (CASTEMI Trial) that caldaret (MCC-135), a novel compound that modulates myocardial calcium handling, when administered prior to PCI did not change residual left ventricular function. The aim of this sub-analysis was to examine if caldaret reduces the frequency of left ventricular dysfunction (LVD) LVEF≤30%, in STEMI patients undergoing primary PCI. Of the 387 patients enrolled in the CASTEMI study, 239 had SPECT data on days 7 and 30, after the infarct. The frequency of LVD for low and high dose caldaret was compared with placebo. At day 30 after the infarct, there was a significant reduction in the frequency of LVD in patients receiving both the low and the high dose of caldaret compared to placebo (see table⇓). In patients with anterior infarct+TIMI 0/1, a 52% reduction in the frequency of LVD was observed already on day 7 (p=0.026). In addition, the frequency of LVEF≤30 was significantly reduced between day7 to 30 in patients treated with both doses of caldaret, while there was no change in the placebo group.